LONDON -- For a country that is said to have lost its industrial base, there are plenty of flourishing engineering companies in the FTSE 100, such as 拢5.2 billion�Smiths Group� (LSE: SMIN ) . This is more than an engineer, it's a global technology business whose five divisions cover everything from contraband detection to medical devices, energy and communications. Should I buy it?
Smiths Group has just published a market-pleasing interim management statement, showing rising underlying revenue across all five of its divisions in the nine months to May 4. Underlying headline operating profit also rose, as did headline operating margin, with the exception of Smiths Medical, where profits have been knocked by a new U.S. medical device tax, and substantial investment in sales and marketing.
Cautious investment
Investor enthusiasm has been tempered by recent management caution, which has been warning of tough trading conditions to come, and loss of revenues due to government spending cuts. Yet the share price has had a solid 12 months, rising 32% against 24% for the FTSE 100 as a whole. Over three years it has slightly underperformed, rising 28% against 32% for the index. Investors can't complain, but they won't be breaking out the bubbly either.
Top 5 Cheap Companies For 2015: Covidien PLC (COV)
Covidien Public Limited Company is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings. It operates its businesses through three segments: Medical Devices, which includes the development, manufacture and sale of endomechanical instruments, energy devices, soft tissue repair products, vascular products, oximetry and monitoring products, airway and ventilation products; Pharmaceuticals, which includes the development, manufacture and distribution of specialty pharmaceuticals and active pharmaceutical ingredients, and Medical Supplies, SharpSafety products and original equipment manufacturer products. In May 2012, it acquired Newport Medical Instruments, Inc. In May 2012, it acquired superDimension, Ltd. In June 2012, the Company acquired Oridion Systems Ltd. In October 2012, its Mallinckrodt acquired CNS Therapeutics, Inc. In January 2013, the Company acquired CV Ingenuity. Advisors' Opinion:- [By WWW.DAILYFINANCE.COM]
Claude Paris/AP Until April 15 approaches every year, it's hard for many Americans to pay much attention to tax issues. But the recent surge in the number of U.S. companies using a popular tax-cutting strategy known as a tax inversion has led to extensive controversy, with proponents of the strategy arguing that it's entirely legal while opponents worry about the loss of U.S. corporate tax revenue. Moreover, political fallout from having well-known companies like Burger King Worldwide (BKW), AbbVie (ABBV) and Medtronic (MDT) flee for foreign countries almost guaranteed that the U.S. government would take action. Earlier this week, the Treasury Department finally fought back, with new rules designed to limit some of the most common ways that companies structure tax inversions, but they fail to address the deeper issue that led to the use of tax inversions and similar tax-saving devices in the first place. What Tax Inversions Are and Why They're a Big Deal The reason that tax inversions have generated so much controversy is that they effectively take away U.S. tax revenue without having much meaningful impact on the way a company does business. A tax inversion involves a U.S. company buying out a foreign company, with the resulting combined business taking the tax home of the foreign company. Because most foreign tax systems have lower tax rates on businesses than the U.S. corporate tax rate of 35 percent, major corporations can save billions of dollars over the long run by moving abroad. Until now, moreover, it was relatively easy for companies to do tax inversions. Despite rules designed to limit their use, tax inversions involved huge U.S. companies merging with much smaller foreign companies. For instance, AbbVie is almost twice as big as its target, Shire, even after Shire shares soared following the buyout announcement. Medtronic has a similar size advantage compared to target Covidien (COV). What the Treasury Did In its notice to the public, the Trea
- [By Dan Carroll]
Finally, Covidien (NYSE: COV ) has also entered the renal denervation race, although this company looks to be behind St. Jude and Medtronic as the leaders. Covidien purchased small-time renal denervation player Maya Medical last year for up to $170 million including milestone payouts, and it also received European approval for its OneShot renal denervation system last year. However, Covidien only launched the OneShot commercially in January, putting it back with Boston Scientific in racing to catch up with St. Jude and Medtronic's advance.
- [By Jesse Solomon]
The latest deals include medical device maker Medtronic's (MDT) $42.9 billion acquisition of rival Coviden (COV), telecom giant Level 3 Communications' (LVLT) $5.7 billion purchase of tw telecom (TWTC), Williams Companies (WMB)' $6 billion controlling stake in natural gas driller Access Midstream Partners (ACMP), and SanDisk's (SNDK) $1.1 billion takeover of flash technology company Fusion-io (FIO).
5 Best Medical Stocks To Own For 2014: Marcolin SpA (MCL)
Marcolin SpA is an Italy-based eyewear manufacturer. It is a manufacturer of glasses and sunglasses for such brands as Tom Ford, Roberto Cavalli and Just Cavalli, Diesel, Montblanc, Tod's and Hogan, Balenciaga, Swarovski, Timberland, DSquared2 and Kenneth Cole. Advisors' Opinion:- [By John McCamant]
Our top stock selection for 2014 has received three Breakthrough Therapy Designations (BTD) by the FDA, and subsequent approval, in November, for Imbruvica, a very safe pill that has shown unprecedented efficacy to treat mantle cell lymphoma (MCL), suggests John McCamant, editor of The Medical Technology Stock Letter.
5 Best Medical Stocks To Own For 2014: Imprimis Pharmaceuticals Inc (IMMY)
Imprimis Pharmaceuticals Inc. is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company�� Transdel cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier. Ketotransdel, the Company�� lead pain product, utilizes the Transdel platform technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), through the skin directly into the underlying tissues where the drug exerts its anti-inflammatory and analgesic effects. Ketotransdel consists of a transdermal formulation of ketoprofen, a non-steroidal anti-inflammatory drug (NSAID), and its Transdel drug delivery system and is being developed for the treatment of acute pain. In July 2013, it acquired intellectual property for IPI-120 from Buderer Drug Company.
Ketotransdel penetrates the skin barrier to reach the targeted underlying tissues where it exerts its localized anti-inflammatory and analgesic effect. Transdel is the Company�� transdermal cream drug delivery platform. It consists of a cream that enables transdermal penetration of drugs avoiding first pass metabolism by the liver and minimizing systemic exposure. The Transdel drug delivery system facilitates the effective dissolution and delivery of a drug across the skin barrier to reach targeted underlying tissues.
Advisors' Opinion:- [By John Udovich]
So far this year, Rexahn Pharmaceuticals, Inc (NYSEMKT: RNN), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and Arrowhead Research Corp (NASDAQ: ARWR) are up 186.3%, 157.2% and 142.5%, respectively, since the start of the year���making them the best performing small cap biotech stocks for 2014. But given their lackluster performance over the past few years, what is the secret behind their phenomenal 2014 rise and will they keep rising? For starters, none of these small caps have really produced anything in the way of blockbuster news:
- [By John Udovich]
The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:
5 Best Medical Stocks To Own For 2014: TESARO Inc (TSRO)
TESARO, Inc. (TESARO), incorporated in March 2010, is a development-stage, oncology-focused biopharmaceutical company for cancer patients. The Company focuses on rolapitant and TSR-011 product. The Company�� marketed products and product candidates in development treat cancer through non-specific damage to cellular components or alter cell metabolism or internal repair mechanisms to the demise of cancer cells.
Rolapitant
Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting (CINV). It is in Phase III clinical trials. CINV, if not prevented by prophylaxis, has the potential to afflict up to 90% or more of cancer patients undergoing chemotherapy, depending upon the type of chemotherapy administered the dosing schedule of the chemotherapy, and the patients' age and gender, among other predisposing factors. Prolonged nausea and vomiting may result in unwanted weight loss, dehydration and malnutrition, as well as hospitalization. The Company has in-licensed the rights to rolapitant from OPKO Health, Inc.
TSR-011
TSR-011 is an orally available ALK inhibitor in preclinical development. ALK is known to be involved in certain types of cancers, including subsets of NSCLC, neuroblastoma and lymphoma. For patients in these subsets, the ALK gene is fused to an activating partner or contains point mutations, resulting in constitutive activation of ALK and the growth of cancer cells and tumor development. Inhibition of ALK in these cancer cells results in cell death and tumor growth inhibition or regression. In August 2011, the United States Food and Drug Administration approved the first ALK inhibitor, developed by Pfizer Inc., Xalkori (crizotinib), which was approved for the treatment of patients with locally advanced or metastatic NSCLC that are ALK positive.
The Company competes with GlaxoSmithKline plc, Roche Holding Ltd! . and Sanofi S.A.
Advisors' Opinion:- [By Ben Levisohn]
Werber and Eckhard’s favorites include Gilead (GILD) and Celgene (CELG), and they find the “risk/reward…compelling” in Medivation (MDVN) and Tesaro (TSRO).
- [By Keith Speights]
Positive response
Clovis wasn't the only company to bring good news about an ovarian cancer drug to ASCO. TESARO� (NASDAQ: TSRO ) announced phase 1 results for�niraparib. Shares of the biotech jumped 16% for the week. - [By Brian Pacampara]
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company TESARO (NASDAQ: TSRO ) has received the dreaded one-star ranking.
No comments:
Post a Comment